Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Completed
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide and dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide and dexamethasone together with bortezomib may kill more cancer cells. PURPOSE: This phase II trial is studying giving cyclophosphamide and dexamethasone together with b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2011
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: Mayo Clinic, Scottsdale, Arizona
Conditions: Multiple Myeloma
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Terminated
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2009
Locations: Palo Verde Hematology/Oncology, Ltd., Glendale, Arizona
Conditions: Diffuse Large B-cell Lymphoma